Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Michael Andreeff, MD, PhD, Zhihong Zeng, PhD, Mary A Kelly, RN, Rui-yu Wang, MD, PhD, Teresa McQueen, BS, Seshagiri Duvvuri, Gul Nowshad, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Elias Jabbour, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD, PhD

Blood (2012) 120 (21): 142.

https://doi.org/10.1182/blood.V120.21.142.142

Published: 2012

Journal Articles

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Maro Ohanian, DO, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Alfonso Quintas-Cardamas, MD, Elias Jabbour, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Stefan Faderl, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1456.

https://doi.org/10.1182/blood.V120.21.1456.1456

Published: 2012

Journal Articles

Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Tapan M. Kadia, M.D., Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Jorge E. Cortes, MD, Naval Daver, MD, Elias J. Jabbour, MD, Charles Asa Koller, Marina Konopleva, MD, PhD, Naveen Pemmaraju, M.D., Marry A Kelly, Rebecca Garris, BSc, Susan O'Brien, Stefan Faderl, MD

Blood (2012) 120 (21): 1501.

https://doi.org/10.1182/blood.V120.21.1501.1501

Published: 2012

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Keyur P. Patel, MD, PhD, Guillermo Garcia Manero, Ohad Benjamini, MD, Gautam Borthakur, M.D., Naveen Pemmaraju, M.D., Tapan M. Kadia, M.D., Naval G. Daver, MD, Aziz Nazha, Rajyalakshmi Luthra, PhD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2484.

https://doi.org/10.1182/blood.V120.21.2484.2484

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.

Syed M. Kazmi, MD, Hagop M. Kantarjian, MD, Kathy M. Tran, Jorge E. Cortes, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Elias J. Jabbour, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Naval Daver, MD, Sherry A. Pierce, RN, BS, Aziz Nazha, Alfonso Quintas-Cardama, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 2587.

https://doi.org/10.1182/blood.V120.21.2587.2587

Published: 2012

Journal Articles

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Hady Ghanem, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Sherry A. Pierce, RN, BS, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 2627.

https://doi.org/10.1182/blood.V120.21.2627.2627

Published: 2012

Journal Articles

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Farhad Ravandi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, PhD, Stuart L. Goldberg, MD, Meir Wetzler, MD, Parameswaran Venugopal, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2630.

https://doi.org/10.1182/blood.V120.21.2630.2630

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Kathy M. Tran, Syed M. Kazmi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Stefan Faderl, MD, Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD

Blood (2012) 120 (21): 2592.

https://doi.org/10.1182/blood.V120.21.2592.2592

Published: 2012

Journal Articles

Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).

Farhad Ravandi, MD, Keyur P. Patel, MD, PhD, Rajyalakshmi Luthra, Ph.D., Sherry A. Pierce, RN, BS, Gautam Borthakur, M.D., Elias J. Jabbour, MD, Tapan M. Kadia, M.D., Naveen Pemmaraju, M.D., Naval Daver, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jorge E Cortes, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2483.

https://doi.org/10.1182/blood.V120.21.2483.2483

Published: 2012

Journal Articles

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Elias J. Jabbour, MD, Naval G. Daver, MD, Tina (Xiao Qin) Dong, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, M.D., Hady Ghanem, MD, Stefan Faderl, MD, Gautam Borthakur, M.D., Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 2824.

https://doi.org/10.1182/blood.V120.21.2824.2824

Published: 2012

Journal Articles

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Farhad Ravandi, MD, Mona Lisa Alattar, MD, Mark J. Levis, MD, PhD, Guillermo Garcia-Manero, MD, Mary A Richie, RN, Naval G. Daver, MD, Stefan Faderl, MD, Michael Andreeff, MD, PhD, Gautam Borthakur, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Michael R. Grunwald, MD, Sara E Dellasala, RN, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 1519.

https://doi.org/10.1182/blood.V120.21.1519.1519

Published: 2012

Journal Articles

Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21

Paolo Strati, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Elias J. Jabbour, MD, Aziz Nazha, Gautam Borthakur, Stefan Faderl, MD, Alfonso Quintás-Cardama, MD, Naval G. Daver, MD

Blood (2012) 120 (21): 1488.

https://doi.org/10.1182/blood.V120.21.1488.1488

Published: 2012

Journal Articles

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Blood (2012) 120 (21): 3572.

https://doi.org/10.1182/blood.V120.21.3572.3572

Published: 2012

Journal Articles

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

Blood (2012) 120 (21): 677.

https://doi.org/10.1182/blood.V120.21.677.677

Published: 2012

Journal Articles

The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 72.

https://doi.org/10.1182/blood.V120.21.72.72

Published: 2012

Journal Articles

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

Young Kwang Chae, MD, MPH, Nianxiang Zhang, Yihua Qiu, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Kevin R. Coombes, PhD, Steven M. Kornblau, MD, PhD

Blood (2012) 120 (21): 891.

https://doi.org/10.1182/blood.V120.21.891.891

Published: 2012

Journal Articles

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 43.

https://doi.org/10.1182/blood.V120.21.43.43

Published: 2012

Journal Articles

Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy

Aziz Nazha, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Sherry A. Pierce, RN, BS, Naval G. Daver, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 4928.

https://doi.org/10.1182/blood.V120.21.4928.4928

Published: 2012

Journal Articles

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Stefan Faderl, MD, Sara E Dellasala, RN, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintás-Cardama, MD, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 4939.

https://doi.org/10.1182/blood.V120.21.4939.4939

Published: 2012

NARROW

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only